Do you want to read an article? Please log in or register.
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Kim D, Blocker S, Cavalieri CC, Cannon S, Cass AS, Olinger A, Bortka B, Gustafson B, Schepers A, Hobbs J, Blackwell L, Holman K, Widman W, Quick A, Grauer D, Lekkala MR, Huang C, Neupane P, Zhang J, Mullangi S, Schieber T
doi: 10.1016/j.cllc.2026.01.007
Lung Cancer
Real-World Clinical Outcomes of Concurrent Chemotherapy and Dose-Escalated Twice-Daily Radiotherapy With Simultaneous Integrated Boost (SIB) for Limited-Stage Small Cell Lung Cancer
Clin Lung Cancer
Celikarslan S, Sezen D, Duman M, Durankus NK, Oymak SE, Esen CSB, Rustamov A, Nasir A, Guclu SB, Kanıtez M, Kaban K, Yumuk F, Selcukbiricik F, Mandel NM, Cesur E, Erus S, Tanju S, Dilege S, Gumus T, Atasoy C, Demirkurek C, Falay O, Demirkol O, Bulutay P, Firat P, Atagun Y, Selek U
doi: 10.1016/j.cllc.2026.03.010
Lung Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
Lung Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Lung Cancer
Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer
J Thorac Oncol
Movsas B, Hu C, Higgins KA, Ross HJ, Jabbour SK, Kozono D, Owonikoko TK, Xiao C, Shoji T, Faller BA, Mohindra P, Dib EG, Brownstein J, Chun SG, Kuzma CS, Kotecha R, Onitilo A, Mulford D, Paulus R, Bradley JD, Bruner DW
doi: 10.1016/j.jtho.2026.104117
COMMENTED
Lung Cancer
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
JAMA Oncol
Rousseau A, Foulon S, Planchard D, Remon J, Barlesi F, Lavaud P, Frelaut M, Aldea M, Parisi C, Gazzah A, Le Pechoux C, Botticella A, Levy A, Simon-Tillaux N, Michiels S, Besse B
doi: 10.1001/jamaoncol.2026.0669
Lung Cancer
A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution
Clin Lung Cancer
Matsuura K, Komaki R, Kono M, Kudo T, Ono A, Kameoka T, Shintani I, Kusaba H, Kawakubo A, Ando Y, Nishihara K, Iwamoto Y, Shoda H, Katsuta T, Kagemoto M
doi: 10.1016/j.cllc.2025.09.003
Lung Cancer
Computer Assisted Nodule Analysis and Risk Yield Outcomes May be Associated with Recurrence after Stereotactic Body Radiation Therapy in Clinical Stage I Non-Small-Cell Lung Cancer
Clin Lung Cancer
Pham D, Thakur N, Park JA, Nie W, Correa M, Wang H, Subramanian M, Weyant M, Johnson CB, Suzuki K
doi: 10.1016/j.cllc.2025.10.008
RECOMMENDED
Lung Cancer
Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
★ 2
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Mountzios G, Weng JK, Zairi E, Hsieh K, Chander P, Dunlop W, Qiao Y, Wang A, Januszewski A
doi: 10.1016/j.cllc.2026.01.005